Skip to main content

Pivotal Trials Put HER2-Mutated NSCLC on Notice

*March 2022*

Note: In this article,  Julien Mazieres, MD, PhD, talks R2D2, while Bob Li, MD, PhD, MPH, highlights DESTINY-Lung01

Also note: In the Destiny trial, Drug-related interstitial lung disease (ILD) and pneumonitis remain an important, identifiable risk.

The R2D2 trial achieved a first by showing that HER2 mutations can be “treatable targets” in patients with previously treated, advanced HER2-mutated non-small cell lung cancer (NSCLC).

“HER2 exon 20 insertions and point mutations are oncogenic drivers found in 1%-2% of patients with [NSCLC],” explained Julien Mazieres, MD, PhD, of the Toulouse University Hospital in France, and colleagues in the study in the Journal of Clinical Oncology (JCO).

They tested trastuzumab (Herceptin) and pertuzumab (Perjeta) with docetaxel in 45 patients in the phase II trial, and concluded that “antibodies targeting HER2 appear to be the best strategy for these patients. The extrapolation of the use of a combination … from the treatment of breast cancer to the treatment of lung cancer appears feasible and promising.” Read more.